Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
PLoS One. 2012;7(2):e31420. doi: 10.1371/journal.pone.0031420. Epub 2012 Feb 7.
CMV status is an important risk factor in immune compromised patients. In hematopoeitic cell transplantations (HCT), both donor and recipient are tested routinely for CMV status by serological assays; however, one might argue that it might also be of relevance to examine CMV status by cellular (i.e., T lymphocyte) assays. Here, we have analyzed the CMV status of 100 healthy blood bank donors using both serology and cellular assays. About half (56%) were found to be CMV seropositive, and they all mounted strong CD8+ and/or moderate CD4+ T cell responses ex vivo against the immunodominant CMV protein, pp65. Of the 44 seronegative donors, only five (11%) mounted ex vivo T cell responses; surprisingly, 33 (75%) mounted strong CD4+ T cell responses after a brief in vitro peptide stimulation culture. This may have significant implications for the analysis and selection of HCT donors.
CMV 状态是免疫功能低下患者的一个重要危险因素。在造血细胞移植（HCT）中，供体和受者通常通过血清学检测来常规检测 CMV 状态；然而，人们可能会认为通过细胞（即 T 淋巴细胞）检测来检查 CMV 状态也很重要。在这里，我们使用血清学和细胞检测方法分析了 100 名健康献血者的 CMV 状态。约有一半（56%）的人被发现 CMV 血清阳性，他们都对免疫优势 CMV 蛋白 pp65 产生了强烈的 CD8+和/或中等强度的 CD4+T 细胞反应。在 44 名血清阴性供体中，只有 5 名（11%）产生了体外 T 细胞反应；令人惊讶的是，33 名（75%）在短暂的体外肽刺激培养后产生了强烈的 CD4+T 细胞反应。这可能对 HCT 供体的分析和选择有重要意义。
